Tinospora cordifolia (guduchi or giloy) is a shrub used in ayurveda as an "immune booster", widely promoted in India during COVID-19. Its best-documented effect in people is a pattern of liver injury with autoimmune features.
Also known as: guduchi, giloy, Tinospora.
The rhinitis trial below gave an extract for 8 weeks; the abstract does not state the amount, so we do not list one.
It is sold in the US as a dietary supplement. Under the 1994 dietary supplement law (DSHEA), FDA does not approve dietary supplements before they are marketed, and the maker, not FDA, is responsible for safety and labeling.
Liver injury: a study at 13 Indian centers described 43 people with liver injury linked to giloy, with a median of 46 days from starting it to symptoms. They had acute hepatitis, a flare of existing liver disease or acute liver failure, often with autoimmune features, and liver injury was judged probable in 67%. The authors conclude giloy can cause hepatitis with autoimmune features and can unmask hidden autoimmune liver disease (Kulkarni 2022). An earlier series of 6 patients reached similar conclusions; most recovered after stopping it, some with steroids, after a median of about 87 days (Nagral 2021).
What other studies show: in a 2005 Indian trial of 75 people with allergic rhinitis, 8 weeks of the extract relieved sneezing, discharge and congestion in more people than placebo (Badar 2005). We found no larger, recent trials.
We could not find a single published half-life or time to peak for Tinospora cordifolia that applies to a supplement dose, so we do not list one. Plant extracts are mixtures of many compounds, so no single figure would describe them.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator